Richard L Page

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/288489/publications.pdf

Version: 2024-02-01

231 papers

51,814 citations

88 h-index 225 g-index

237 all docs

237 docs citations

times ranked

237

30837 citing authors

#	Article	IF	CITATIONS
1	ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease. Circulation, 2006, 114, e84-231.	1.6	3,195
2	ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). Circulation, 2006, 113, e463-654.	1.6	2,927
3	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Circulation, 2005, 112, e154-235.	1.6	2,179
4	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2006, 114, e257-354.	1.6	2,120
5	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, e1-e157.	2.8	1,587
6	ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease. Journal of the American College of Cardiology, 2006, 48, e1-e148.	2.8	1,564
7	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2008, 117, e350-408.	1.6	1,358
8	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2006, 48, e247-e346.	2.8	1,280
9	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Circulation, 2007, 116, e148-304.	1.6	1,247
10	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Journal of the American College of Cardiology, 2010, 56, e50-e103.	2.8	1,150
11	ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary. Journal of the American College of Cardiology, 2007, 50, 1707-1732.	2.8	1,091
12	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary. Journal of the American College of Cardiology, 2006, 48, 854-906.	2.8	1,044
13	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2006, 114, e385-484.	1.6	1,031
14	Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. New England Journal of Medicine, 2009, 360, 668-678.	27.0 0.784314	1,029
15	the American Association for Vascular Surgery/Society for Vascular Surgery,âŽâŽAAVS/SVS when Guideline initiated, now merged into SVSSociety for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task	2.8	1,012
16	Force on Practice Guidelines, Journal of the American College of Cardiology, 2005, 47, 1239-1312. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2018, 72, e91-e220.	2.8	991
17	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Interventionâ€"Summary Article. Circulation, 2006, 113, 156-175.	1.6	987
18	American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Circulation, 2008, 118, 1497-1518.	1.6	903

#	Article	IF	CITATIONS
19	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2013, 127, e283-352.	1.6	803
20	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2011, 123, e269-367.	1.6	747
21	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Journal of the American College of Cardiology, 2013, 61, e6-e75.	2.8	736
22	2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Circulation, 2008, 117, 261-295.	1.6	715
23	ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. Journal of the American College of Cardiology, 2007, 50, e159-e242. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A	2.8	709
24	report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing) Tj ETQq0 0 0 rgBT Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm	/Oyerlock	10 Tf 50 5
25	Society. Europace, 2006, 8, 651-745. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. Circulation, 2007, 116, e418-99.	1.6	644
26	Use of Automated External Defibrillators by a U.S. Airline. New England Journal of Medicine, 2000, 343, 1210-1216.	27.0	620
27	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq1	1.0.7843	14 rgBT /0 618
28	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary. European Heart Journal, 2006, 27, 1979-2030.	2.2	612
29	ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary. Circulation, 2007, 116, 1971-1996.	1.6	612
30	Quality of Life in the Antiarrhythmics Versus Implantable Defibrillators Trial. Circulation, 2002, 105, 589-594. ACCIAHA/ESC 2006 guidelines for management of patients with ventricular ambuthmias and the	1.6	588
31	prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias) Tj ETQq1 1	d: 7 84314	546T /Over
32	Rhythm Association and the Heart R. Europace, 2006, 8, 746-837. ACC/AHA/SCAI Practice Guidelines, February 21, 2006. Circulation, 2006, 113, e166-286.	1.6	525
33	Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. JAMA - Journal of the American Medical Association, 2007, 297, 2502.	7.4	497
34	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2018, 138, e272-e391.	1.6	468
35	prevention of sudden cardiac deathexecutive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with) Tj ETQq1 1 0	. 78 4314 r	g <mark>854</mark> /Over <mark>lo</mark>
36	with the European Heart Rhythm Associat. European Heart Journal, 2006, 27, 2099-2140. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary. Heart Rhythm, 2018, 15, e190-e252.	0.7	448

#	Article	IF	CITATIONS
37	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2006, 47, e1-e121.	2.8	435
38	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on) Tj ETQq	000 rgB	Г <u>Д</u> Qyerlock
39	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Journal of the American College of Cardiology, 2018, 72, 1677-1749.	2.8	382
40	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary. Heart Rhythm, 2008, 5, 934-955.	0.7	367
41	Hands-Only (Compression-Only) Cardiopulmonary Resuscitation: A Call to Action for Bystander Response to Adults Who Experience Out-of-Hospital Sudden Cardiac Arrest. Circulation, 2008, 117, 2162-2167.	1.6	335
42	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Journal of the American College of Cardiology, 2016, 67, e27-e115.	2.8	325
43	2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2012, 126, 1784-1800.	1.6	321
44	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Circulation, 2016, 133, e506-74.	1.6	320
45	Ultraprocessed food and chronic noncommunicable diseases: A systematic review and metaâ€analysis of 43 observational studies. Obesity Reviews, 2021, 22, e13146.	6.5	298
46	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary. Circulation, 2006, 114, 700-752.	1.6	294
47	Cardiac Arrest in Pregnancy. Circulation, 2015, 132, 1747-1773.	1.6	290
48	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Heart Rhythm, 2008, 5, e1-e62.	0.7	283
49	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq1	1 0.7843 2.8	14 rgBT /0 262
50	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm, 2018, 15, e73-e189.	0.7	262
51	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease: Executive Summary. Catheterization and Cardiovascular Interventions, 2010, 76, E43-86.	1.7	260
52	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, e153-e203.	0.8	260
53	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Circulation, 2018, 138, e210-e271.	1.6	250
54	American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Journal of the American College of Cardiology, 2008, 52, 1179-1199.	2.8	241

#	Article	IF	CITATIONS
55	Diabetes Mellitus, Glycemic Control, and Risk of Atrial Fibrillation. Journal of General Internal Medicine, 2010, 25, 853-858.	2.6	238
56	Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter. Circulation, 2009, 120, 1174-1180.	1.6	228
57	ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower) Tj ETQq0 0 0	2.2 rgBT /Ov	214 verlock 10 Tf !
58	Association for Vascular Surgery/Society for Vascular Surgery,âŽSociety for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional		

#	Article	IF	Citations
73	Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. American Heart Journal, 2001, 142, 498-501.	2.7	124
74	Treatment of Cardiac Arrhythmias During Pregnancy. Drug Safety, 1999, 20, 85-94.	3.2	119
75	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Journal of the American College of Cardiology, 2014, 64, 1143-1177.	2.8	118
76	ACC/AHA 2006 Guideline Update on Perioperative Cardiovascular Evaluation for Noncardiac Surgery: Focused Update on Perioperative Beta-Blocker Therapy. Journal of the American College of Cardiology, 2006, 47, 2343-2355.	2.8	117
77	Newly Diagnosed Atrial Fibrillation. New England Journal of Medicine, 2004, 351, 2408-2416.	27.0	115
78	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on) Tj ETQq	0.00 rgBT 0.7	Oyerlock
79	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq1	1 0.7843 0.7	14 rgBT /0 114
80	Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death. Circulation, 2016, 133, 1715-1727.	1.6	108
81	Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Journal of the American College of Cardiology, 2000, 36, 794-802.	2.8	106
82	Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace, 2009, 11, 860-885.	1.7	104
83	Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. American Journal of Cardiology, 2003, 92, 941-946.	1.6	102
84	Asymptomatic Atrial Fibrillation. Progress in Cardiovascular Diseases, 2005, 48, 79-87.	3.1	102
85	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Circulation, 2014, 130, 94-125.	1.6	102
86	Effects of repeated electrical defibrillations on cardiac troponin I levels. American Journal of Cardiology, 1999, 83, 270-272.	1.6	97
87	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary. Circulation, 2016, 133, e471-505.	1.6	96
88	American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation, 2008, 118, 1497-1518.	1.6	90
89	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary. Journal of the American College of Cardiology, 2016, 67, 1575-1623.	2.8	86
90	Initial energy for elective external cardioversion of persistent atrial fibrillation. American Journal of Cardiology, 2000, 86, 348-350.	1.6	84

#	Article	IF	Citations
91	Biventricular pacing decreases the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy. American Journal of Cardiology, 2001, 87, 1208-1210.	1.6	84
92	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. Heart Rhythm, 2016, 13, e136-e221.	0.7	84
93	Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. American Journal of Cardiology, 2001, 88, 974-979.	1.6	83
94	Community Approaches to Improve Resuscitation After Out-of-Hospital Sudden Cardiac Arrest. Circulation, 2010, 121, 1134-1140.	1.6	83
95	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 1303-1338.	0.8	73
96	Radiofrequency Catheter Ablation of Idiopathic Recurrent Ventricular Tachycardia with Right Bundle Branch Block, Left Axis Morphology. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 327-336.	1.2	62
97	Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. Journal of the American College of Cardiology, 1995, 25, 984-988.	2.8	62
98	American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Heart Rhythm, 2008, 5, e1-e21.	0.7	61
99	Dronedarone in patients with congestive heart failure: insights from ATHENA. European Heart Journal, 2010, 31, 1717-1721.	2.2	61
100	Antiarrhythmic drugs in pregnancy. Current Opinion in Cardiology, 2001, 16, 40-45.	1.8	59
101	Drug therapy for atrial fibrillation: where do we go from here?. Nature Reviews Drug Discovery, 2005, 4, 899-910.	46.4	59
102	Rhythm- and Rate-Controlling Effects of Dronedarone in Patients With Atrial Fibrillation (from the) Tj ETQq0 0 0 0	rgBT/Over	lock 10 Tf 50
103	Effects of resynchronization therapy on sympathetic activity in patients with depressed ejection fraction and intraventricular conduction delay due to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 2002, 89, 1047-1051.	1.6	54
104	Defibrillation Aboard a Commercial Aircraft. Circulation, 1998, 97, 1429-1430.	1.6	52
105	Fish Oil and Post-Operative Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2194-2196.	2.8	52
106	Rationale and Design of ATHENA: A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in PatiENts with Atrial Fibrillation/Atrial Flutter. Journal of Cardiovascular Electrophysiology, 2007, 19, 071121154351003-???.	1.7	51
107	Serotonin Reuptake Inhibitor (Paxil) Does Not Prevent the Vasovagal Reaction Associated With Carotid Sinus Massage and/or Lower Body Negative Pressure in Healthy Volunteers. Circulation, 2002, 106, 1500-1504.	1.6	50
108	Genicular Artery Embolization to Improve Pain and Function in Early-Stage Knee Osteoarthritis—24-Month Pilot Study Results. Journal of Vascular and Interventional Radiology, 2020, 31, 1453-1458.	0.5	46

#	Article	IF	Citations
109	ACC/AHA/SCAI 2005 guideline update for percutaneous coronary interventionâé"summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary) Tj ETQq1	1 ¹ 0.78431	.45gBT /O∨
110	Baroreflex Gain Predicts Blood Pressure Recovery During Simulated Ventricular Tachycardia in Humans. Circulation, 1999, 100, 381-386.	1.6	44
111	2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, e127-e145.	0.8	44
112	Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Journal of the American College of Cardiology, 2016, 67, 1624-1638.	2.8	43
113	Effect of continuous vagal enhancement on concealed conduction and refractoriness within the atrioventricular node. American Journal of Cardiology, 1996, 77, 260-265.	1.6	42
114	Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Circulation, 2016, 133, e575-86.	1.6	42
115	Management of arrhythmia syndromes during pregnancy. Current Opinion in Cardiology, 2014, 29, 36-44.	1.8	40
116	Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. American Heart Journal, 2006, 151, 1043-1049.	2.7	38
117	Automated External Defibrillators: Technical Considerations and Clinical Promise. Annals of Internal Medicine, 2001, 135, 990.	3.9	37
118	Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-response. American Heart Journal, 2002, 143, 643-649.	2.7	36
119	High-frequency ventricular ectopy can increase sympathetic neural activity in humans. Heart Rhythm, 2010, 7, 497-503.	0.7	35
120	Cardiac Arrest at Exercise Facilities. Journal of the American College of Cardiology, 2013, 62, 2102-2109.	2.8	34
121	Reflex Control of Sympathetic Activity During Simulated Ventricular Tachycardia in Humans. Circulation, 1999, 100, 628-634.	1.6	33
122	Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace, 2011, 13, 1118-1126.	1.7	33
123	Effects of antiarrhythmic medication on implantable cardioverter-defibrillator function. American Journal of Cardiology, 2000, 85, 1481-1485.	1.6	32
124	Racial Differences in Outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). Circulation, 2003, 108, 67-72.	1.6	32
125	Efficacy of Azimilide for the Maintenance of Sinus Rhythm in Patients With Paroxysmal Atrial Fibrillation in the Presence and Absence of Structural Heart Disease. American Journal of Cardiology, 2006, 98, 215-218.	1.6	32
126	Approach to the Diagnosis and Initial Management of the Stable Adult Patient With a Wide Complex Tachycardia. American Journal of Cardiology, 2008, 101, 1456-1466.	1.6	32

#	Article	IF	Citations
127	The ω-3 fatty acids for Prevention of Post-Operative Atrial Fibrillation trial—rationale and design. American Heart Journal, 2011, 162, 56-63.e3.	2.7	31
128	Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace, 2014, 16, 174-181.	1.7	29
129	Influence of metoprolol on heart rate variability in survivors of remote myocardial infarction. American Journal of Cardiology, 1996, 77, 557-560.	1.6	28
130	Diagnostic Approach to Narrow Complex Tachycardia with VA Block. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2984-2988.	1.2	27
131	Effect of radiofrequency ablation on atrial mechanical function in patients with atrial flutter. American Journal of Cardiology, 1999, 84, 420-425.	1.6	27
132	Increased sympathetic activity after atrioventricular junction ablation in patients with chronic atrial fibrillation. Journal of the American College of Cardiology, 2000, 36, 151-158.	2.8	27
133	Effect of P-Wave Timing During Supraventricular Tachycardia on the Hemodynamic and Sympathetic Neural Response. Circulation, 2001, 103, 96-101.	1.6	27
134	Effects of Prolonged Spaceflight on Atrial Size, Atrial Electrophysiology, and Risk of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005959.	4.8	26
135	Atrioventricular Junction Ablation Followed by Resynchronization Therapy in Patients with Congestive Heart Failure and Atrial Fibrillation (AVERT-AF) Study Design. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 1081-1088.	1.2	25
136	The Automated External Defibrillator. Journal of Cardiovascular Electrophysiology, 2007, 18, 896-899.	1.7	23
137	Longâ€Term Outcome of Patients with Bifascicular Block and Unexplained Syncope Following Cardiac Pacing. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1126-1131.	1.2	23
138	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: Executive summary. Heart Rhythm, 2016, 13, e92-e135.	0.7	23
139	Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. American Heart Journal, 2003, 146, 489-493.	2.7	22
140	Reverse total shoulder arthroplasty compared to stemmed hemiarthroplasty for proximal humeral fractures: a registry analysis of 5946 patients. Journal of Shoulder and Elbow Surgery, 2020, 29, 2538-2547.	2.6	22
141	Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. Heart Rhythm, 2004, 1, 435-440.	0.7	21
142	Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan-Stakeholder Critical Path Registry Model: A Cardiac Safety Research Consortium "Incubator― Think Tank. American Heart Journal, 2010, 159, 17-24.e1.	2.7	20
143	Correlation Between Time-Domain Measures of Heart Rate Variability and Scatterplots in Patients With Healed Myocardial Infarcts and the Influence of Metoprolol. American Journal of Cardiology, 1997, 79, 412-414.	1.6	18
144	Twelve-month work–related outcomes following hip fracture in patients under 65 years of age. Injury, 2017, 48, 701-707.	1.7	18

#	Article	lF	Citations
145	Medical management of atrial fibrillation: Future directions. Heart Rhythm, 2007, 4, S91-S94.	0.7	17
146	Azimilide for the Treatment of Atrial Fibrillation, Atrial Flutter, and Paroxysmal Supraventricular Tachycardia: Results of a Randomized Trial and Insights on the Concordance of Symptoms and Recurrent Arrhythmias. Journal of Cardiovascular Electrophysiology, 2008, 19, 172-177.	1.7	17
147	Quality of Evidence Underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the Management of Atrial Fibrillation. JAMA Cardiology, 2017, 2, 319.	6.1	17
148	Predictors of recovery in cyclists hospitalised for orthopaedic trauma following an on-road crash. Accident Analysis and Prevention, 2017, 106, 341-347.	5 . 7	17
149	Core Set of Radiographic Parameters for Shoulder Arthroplasty Monitoring. JBJS Open Access, 2019, 4, e0025.	1.5	17
150	Selective radiofrequency ablation of the "slow―atrioventricular nodal pathway for control of the ventricular response to atrial fibrillation. American Journal of Cardiology, 1996, 77, 1358-1361.	1.6	16
151	Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. American Journal of Cardiology, 2001, 88, 446-448.	1.6	16
152	Arrhythmias occurring during pregnancy. Journal of Interventional Cardiac Electrophysiology, 2002, 6, 136-139.	1.0	16
153	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Heart Rhythm, 2014, 11, 1270-1303.	0.7	16
154	The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial. Trials, 2016, 17, 395.	1.6	16
155	Risk stratification for arrhythmic events in patients with asymptomatic pre-excitation: A systematic review for the 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. Heart Rhythm, 2016, 13, e222-e237.	0.7	16
156	Psychogenic pseudosyncope: Not always a diagnosis of exclusion. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 480-486.	1.2	15
157	Initial experience with a high-impedance tined endocardial pacemaker lead: Evidence for increased lead failure. American Heart Journal, 1997, 134, 161-164.	2.7	14
158	Determinants of Nonthoracotomy Biphasic Defihrillation. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 60-64.	1.2	14
159	Wenckebach Periodicity at Rest That Normalizes With Tachycardia in a Family With a NKX2.5 Mutation. American Journal of Cardiology, 2012, 110, 1646-1650.	1.6	14
160	Pâ \in Wave Amplitude and PR Changes in Patients With Inappropriate Sinus Tachycardia: Findings Supportive of a Central Mechanism. Journal of the American Heart Association, 2018, 7, .	3.7	14
161	Monocortical fixation of the coracoid in the Latarjet procedure is significantly weaker than bicortical fixation. Knee Surgery, Sports Traumatology, Arthroscopy, 2019, 27, 239-244.	4.2	14
162	Management of ventricular arrhythmias. Journal of the American College of Cardiology, 1999, 34, 621-630.	2.8	13

#	Article	IF	Citations
163	Pharmacological therapy of atrial fibrillation. Expert Opinion on Investigational Drugs, 2007, 16, 169-179.	4.1	13
164	Restoring Sinus Rhythm Improves Baroreflex Function in Patients With Persistent Atrial Fibrillation. Journal of the American Heart Association, 2016, 5, .	3.7	13
165	Sympathoexcitation is attenuated during low level lower body negative pressure in subjects who develop pre-syncope. Clinical Autonomic Research, 2003, 13, 208-213.	2.5	12
166	Selective parasympathetic denervation following posteroseptal ablation for either atrioventricular nodal reentrant tachycardia or accessory pathways. American Journal of Cardiology, 2000, 85, 875-878.	1.6	11
167	Antiarrhythmic drugs in pregnancy. Expert Review of Cardiovascular Therapy, 2015, 13, 1433-1444.	1.5	11
168	Another Shock for Sudden Death Prevention after Myocardial Infarction. New England Journal of Medicine, 2018, 379, 1274-1275.	27.0	11
169	The road to recovery for vulnerable road users hospitalised for orthopaedic injury following an on-road crash. Accident Analysis and Prevention, 2019, 132, 105279.	5.7	11
170	Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines–Atrial Fibrillation Registry. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008961.	4.8	11
171	Azimilide dihydrochloride: a new class III anti-arrhythmic agent. Expert Opinion on Investigational Drugs, 2000, 9, 2705-2715.	4.1	10
172	The Automated External Defibrillator: Critical Link in the Chain of Survival. Annual Review of Medicine, 2003, 54, 235-243.	12.2	10
173	Short QT. Circulation, 2007, 116, 686-688.	1.6	10
174	Dronedarone. Nature Reviews Drug Discovery, 2009, 8, 769-770.	46.4	10
175	Out-of-Hospital Cardiac Arrest — Are Drugs Ever the Answer?. New England Journal of Medicine, 2016, 374, 1781-1782.	27.0	10
176	The Role of the Baroreflex in TiltÂTableÂTesting. JACC: Clinical Electrophysiology, 2016, 2, 812-817.	3.2	10
177	Clinical Characteristics and Outcome of Patients with Situational Syncope Compared to Patients with Vasovagal Syncope. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 591-595.	1.2	10
178	Operative shoulder instability injury management in Australian Football League players: A case series. Journal of Science and Medicine in Sport, 2018, 21, 760-764.	1.3	10
179	Effect of glenosphere size on reverse shoulder arthroplasty revision rate: an analysis from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Journal of Shoulder and Elbow Surgery, 2022, 31, e289-e301.	2.6	10
180	Advances in Resuscitation. Circulation, 2012, 126, 991-1002.	1.6	9

#	Article	IF	Citations
181	The Right Place at the Right Time. Circulation, 2017, 135, 1120-1122.	1.6	9
182	Diagnosis of ICD Lead Failure Using Continuous Event Marker Recording. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 1331-1334.	1.2	8
183	The Effect of Biphasic Defibrillation on the Immediate Pacing Threshold of a Dedicated Bipolar, Steroid-Eluting Lead. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 1229-1233.	1.2	8
184	Evaluation of Outpatients Experiencing Implantable Cardioverter Defibrillator Shocks Associated with Minimal Symptoms. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 938-943.	1.2	7
185	Effect of biphasic endocardial countershock on pacing threskolds in humans. American Journal of Cardiology, 1996, 77, 527-528.	1.6	7
186	Effects of Azimilide on Heart Rate and ECG Conduction Intervals during Sinus Rhythm in Patients with a History of Atrial Fibrillation. Journal of Clinical Pharmacology, 2002, 42, 388-394.	2.0	7
187	Latency of ECG Displays of Hospital Telemetry Systems. Circulation, 2012, 126, 1665-1669.	1.6	7
188	Bidisomide (SC-40230), a new antiarrhythmic agent: Initial study of tolerability and pharmacokinetics. Clinical Pharmacology and Therapeutics, 1992, 51, 371-378.	4.7	6
189	Biphasic Versus Monophasic Shock Waveform for Conversion of Atrial Fibrillation. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 290-291.	1.0	6
190	Antiarrhythmic Drugs for All Patients With an ICD?. JAMA - Journal of the American Medical Association, 2006, 295, 211.	7.4	6
191	Ventricular Arrhythmias in the Elderly. Clinics in Geriatric Medicine, 2012, 28, 665-677.	2.6	6
192	Ongoing Management of Patients With Supraventricular Tachycardia. JAMA Cardiology, 2017, 2, 332.	6.1	6
193	The Closing Argument for Surgical Left Atrial Appendage Occlusion. New England Journal of Medicine, 2021, 384, 2154-2155.	27.0	6
194	Propafenone. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 204-206.	1.0	5
195	Interaction of a commercial heart rate monitor with implanted pacemakers. American Journal of Cardiology, 1999, 83, 790-792.	1.6	5
196	Automated External Defibrillator Use by Police Responders. Circulation, 2002, 106, 1030-1033.	1.6	5
197	Pharmacological therapy for atrial fibrillation: current options and new agents. Expert Opinion on Investigational Drugs, 2009, 18, 417-431.	4.1	5
198	The pathophysiologic mechanisms associated with hypotensive susceptibility. Clinical Autonomic Research, 2016, 26, 261-268.	2.5	5

#	Article	IF	Citations
199	Utility of transtelephonic ECG monitoring in evaluating discharges from a third-generation implantable cardioverter defibrillator. Journal of Electrocardiology, 1993, 26, 235-238.	0.9	4
200	Heart Rate During Spontaneous and Induced Paroxysmal Supraventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 2155-2157.	1.2	4
201	The Hot Can: ICD Failure Presenting as Severe Shoulder Pain. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 396-397.	1.2	4
202	Poor baroreflex gain is a marker of heightened sympathetic activity post-tachycardia termination in humans. Clinical Autonomic Research, 2003, 13, 443-446.	2.5	4
203	Guidance for the Heart Rhythm Society Pertaining to Interactions with Industry. Heart Rhythm, 2011, 8, e19-e25.	0.7	4
204	Predicting fracture outcomes from clinical registry data using artificial intelligence supplemented models for evidence-informed treatment (PRAISE) study protocol. PLoS ONE, 2021, 16, e0257361.	2.5	4
205	The AED in resuscitation: it's not just about the shock. Transactions of the American Clinical and Climatological Association, 2011, 122, 347-55.	0.5	4
206	Total shoulder replacement stems in osteoarthritis—short, long, or reverse? An analysis of the impact of crosslinked polyethylene. Journal of Shoulder and Elbow Surgery, 2022, 31, 2249-2255.	2.6	4
207	Arrhythmias During Pregnancy. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 278-282.	1.0	3
208	Intracardiac shunts resulting from transseptal catheterization for ablation of accessory pathways in otherwise normal hearts. American Journal of Cardiology, 1998, 82, 391-392.	1.6	3
209	Early Recurrence of Atrial Fibrillation:. Journal of Cardiovascular Electrophysiology, 2004, 15, 898-900.	1.7	3
210	Public Access Defibrillation. Heart Failure Clinics, 2011, 7, 269-276.	2.1	3
211	Treatment of supraventricular tachycardias with transcatheter delivery of radiofrequency current. American Journal of Medicine, 1992, 93, 549-557.	1.5	2
212	Use of transesophageal atrial pacing with adenosine infusion to evaluate ventricular preexcitation. American Journal of Cardiology, 1995, 75, 548-550.	1.6	2
213	Asymptomatic Atrial Fibrillation. Chest, 2001, 119, 628-631.	0.8	2
214	Relation of Echocardiographic Wall Motion Score Index and Response to Dobutamine Stress to Defibrillation Threshold at the Time of Implantation of a Cardiac Defibrillator. American Journal of Cardiology, 2005, 95, 1099-1101.	1.6	2
215	Acute Treatment of Patients With Supraventricular Tachycardia. JAMA Cardiology, 2016, 1, 483.	6.1	2
216	Automatic External Cardioverter-Defibrillator Therapy. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 260-262.	1.0	1

#	Article	IF	CITATIONS
217	Arrhythmias in Pregnancy. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 227-229.	1.0	1
218	The President's page: The Heart Rhythm Society launches new strategic plan. Heart Rhythm, 2010, 7, 722-723.	0.7	1
219	To the Editor: Responseâ€"Irreplaceable antiarrhythmic medications are disappearing: the case of quinidine. Heart Rhythm, 2010, 7, 863-864.	0.7	1
220	"Vasovagal―Response during Ventricular Fibrillation: Incidence and Implications. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 376-382.	1.2	1
221	The subcutaneous defibrillator: Modest step or quantum leap?. Heart Rhythm, 2017, 14, 1464-1465.	0.7	1
222	The Australian ankle syndesmosis injury survey. Injury, 2022, 53, 2304-2310.	1.7	1
223	Propafenone. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 288-291.	1.0	0
224	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 31-34.	1.0	0
225	New treatment options for stroke prevention in atrial fibrillation. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 341-349.	0.9	O
226	Public Access Defibrillation. Cardiac Electrophysiology Clinics, 2009, 1, 33-40.	1.7	0
227	Acute Antiarrhythmic Therapy of Ventricular Tachycardia and Ventricular Fibrillation. Cardiac Electrophysiology Clinics, 2010, 2, 429-441.	1.7	O
228	Mechanisms of sinus node cycle length changes during ventricular fibrillation. Clinical Autonomic Research, 2015, 25, 399-406.	2.5	0
229	The US Food and Drug Administration Premarket Approval Process and the 515 Program Initiative. JAMA Cardiology, 2016, 1, 119.	6.1	0
230	Do non-steroidal anti-inflammatory drugs impair fracture healing? A survey of Australian orthopaedic surgeons. Journal of Pharmacy Practice and Research, 2017, 47, 393-395.	0.8	0
231	Arrhythmias in Pregnancy and Postpartum. , 2011, , 339-354.		0